Standard or Comprehensive Radiation Therapy in Treating Patients with Early-Stage Breast Cancer Previously Treated with Chemotherapy and Surgery

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeAgeTrial IDs
Phase IIIBiomarker/Laboratory analysis, Treatment18 and overNSABP-B-51/RTOG-1304
NCI-2012-03198, NSABP PROTOCOL B-51/RTOG PROTOCOL 1304, NSABP-B-51, NCT01872975

Trial Description

Summary

This randomized phase III trial studies radiation therapy to the breast, chest wall and lymph nodes (comprehensive) compared to standard radiation therapy to the breast in treating patients with early-stage breast cancer previously treated with chemotherapy and surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with early-stage breast cancer.

Further Study Information

PRIMARY OBJECTIVES:

I. To evaluate whether the addition of chest wall + regional nodal radiation therapy (XRT) after mastectomy or breast + regional nodal XRT after breast conserving surgery will significantly reduce the rate of events for invasive breast cancer recurrence-free interval (IBC-RFI) in patients who present with histologically positive axillary nodes but convert to histologically negative axillary nodes following neoadjuvant chemotherapy.

SECONDARY OBJECTIVES:

I. To evaluate whether the addition of chest wall + regional nodal XRT after mastectomy or breast + regional nodal XRT after breast conserving surgery will significantly prolong overall survival (OS) in patients who present with histologically positive axillary nodes but convert to histologically negative axillary nodes following neoadjuvant chemotherapy.

II. To evaluate whether the addition of chest wall + regional nodal XRT after mastectomy or breast + regional nodal XRT after breast conserving surgery will significantly reduce the rates of events for local-regional recurrence-free interval (LRRFI) in patients who present with histologically positive axillary nodes but convert to histologically negative axillary nodes following neoadjuvant chemotherapy.

III. To evaluate whether the addition of chest wall + regional nodal XRT after mastectomy or breast + regional nodal XRT after breast conserving surgery will significantly reduce the rate of events for distant recurrence-free interval (DRFI) in patients who present with histologically positive axillary nodes but convert to histologically negative axillary nodes following neoadjuvant chemotherapy.

IV. To compare the rates of disease-free survival (DFS)-ductal carcinoma in situ (DCIS) by treatment arm.

V. To compare the rates of second primary cancer by treatment arm.

VI. To compare the effect of adding XRT on the cosmetic outcomes in mastectomy patients who have had reconstruction.

VII. To compare the effect of adding XRT on quality of life including arm problems, lymphedema, pain, and fatigue.

VIII. To evaluate the toxicity associated with each of the radiation therapy regimens.

IX. To determine whether computed tomography (CT)-based conformal methods (intensity-modulated radiation therapy [IMRT] and 3-dimensional conformal radiation therapy [3DCRT]) for chest-wall + regional nodal XRT post mastectomy and regional nodal XRT with breast XRT following breast conserving surgery are feasible in a multi-institutional setting and whether dose-volume analyses can be established to assess treatment adequacy and to develop normal tissue complication probabilities (NTCP) for the likelihood of toxicity.

X. To compare the effect of XRT in patients receiving mastectomy and in patients receiving lumpectomy.

XI. To examine the role of proliferation measures as a prognosticator for patients with residual disease after neoadjuvant chemotherapy.

XII. To develop predictors of the degree of reduction in local regional recurrence (LRR).

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients are assigned to 1 of 2 treatment groups.

GROUP IA: Lumpectomy patients undergo whole breast radiation therapy using IMRT or 3D-CRT once daily (QD) 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.

GROUP IB: Mastectomy patients do not undergo radiation therapy.

ARM II: Patients are assigned to 1 of 2 treatment groups.

GROUP IIA: Lumpectomy patients undergo regional nodal radiation therapy with whole breast radiation therapy using IMRT or 3D-CRT QD 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity QD 5 days a week for 1-1/2 weeks.

GROUP IIB: Mastectomy patients undergo regional nodal radiation therapy using IMRT or 3D-CRT QD 5 days a week for 5 weeks.

All patients also receive systemic therapy as planned (hormonal therapy for patients with hormone-receptor positive breast cancer and trastuzumab or other anti-human epidermal growth factor receptor 2 [HER2] therapy for patients with breast cancer that is HER2-positive).

After completion of study treatment, patients are followed up at 6, 12, 18, and 24 months and then yearly for 8 years.

Eligibility Criteria

Inclusion Criteria:

Patient who have undergone either a total mastectomy or a lumpectomy are eligible; patients who have had a nipple-sparing mastectomy are eligible

At the time of definitive surgery, all removed axillary nodes must be histologically free from cancer; acceptable procedures for assessment of axillary nodal status at the time of surgery include:

Axillary node dissection

Sentinel node biopsy alone provided that at least 2 sentinel lymph nodes are removed; removal of at least 3 sentinel lymph nodes and use of dual tracer for lymphatic mapping are strongly recommended or

Sentinel node biopsy followed by axillary node dissection

Note: patients are eligible whether there is residual invasive carcinoma in the surgical breast specimen or whether there is evidence of pathologic complete response; patients who are found to be pathologically node-positive at the time of surgery, based on sentinel node biopsy alone, are candidates for A011202, a study developed by the Alliance in Oncology, an National Cancer Institute (NCI) Cooperative Group; if A011202 is open at the investigator's institution, patients should be approached about participating in the A011202 study

For patients who receive adjuvant chemotherapy after surgery, a maximum of 12 weeks of intended chemotherapy may be administered but must be completed before randomization; (if treatment delays occur, chemotherapy must be completed within 14 weeks); the dose and schedule of the adjuvant chemotherapy are at the investigator's discretion; Note: it is preferred that all intended chemotherapy be administered in the neoadjuvant setting

Patients must have had HER2 testing performed on the primary breast tumor before neoadjuvant chemotherapy according to the current ASCO/CAP guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer (http://www.asco.org); patients who have a primary tumor that is either HER2-positive or HER2-negative are eligible

The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Patient must have clinically T1-3, N1 breast cancer at the time of diagnosis (before neoadjuvant therapy); clinical axillary nodal involvement can be assessed by palpation, ultrasound, CT scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, or PET/CT scan

Patient must have had pathologic confirmation of axillary nodal involvement at presentation (before neoadjuvant therapy) based on either a positive fine needle aspirate (FNA) (demonstrating malignant cells) or positive core needle biopsy (demonstrating invasive adenocarcinoma); the FNA or core needle biopsy can be performed either by palpation or by image guidance; documentation of axillary nodal positivity by sentinel node biopsy (before neoadjuvant therapy) is not permitted

Patients must have had estrogen receptor (ER) analysis performed on the primary breast tumor before neoadjuvant therapy according to current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for hormone receptor testing; if negative for ER, assessment of progesterone receptor (PgR) must also be performed according to current ASCO/CAP guideline recommendations for hormone receptor testing (http://www.asco.org)

Patient must have completed a minimum of 12 weeks of standard neoadjuvant chemotherapy consisting of an anthracycline and/or taxane-based regimen

Patients with HER2-positive tumors must have received neoadjuvant trastuzumab or other anti-HER2 therapy (either with all or with a portion of the neoadjuvant chemotherapy regimen), unless medically contraindicated

For patients who undergo lumpectomy, the margins of the resected specimen or re-excision must be histologically free of invasive tumor and DCIS as determined by the local pathologist; additional operative procedures may be performed to obtain clear margins; if tumor is still present at the resected margin after re-excision(s), the patient must undergo total mastectomy to be eligible; (patients with margins positive for lobular carcinoma in situ [LCIS] are eligible without additional resection)

For patients who undergo mastectomy, the margins must be histologically free of residual (microscopic or gross) tumor

The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines

Patients with pathologic staging of ypN0(i+) or ypN0(mol+) are eligible

The interval between the last surgery for breast cancer (including re-excision of margins) and randomization must be no more than 56 days; also, if adjuvant chemotherapy was administered, the interval between the last chemotherapy treatment and randomization must be no more than 56 days

The patient must have recovered from surgery with the incision completely healed and no signs of infection

If adjuvant chemotherapy was administered, chemotherapy-related toxicity that may interfere with delivery of radiation therapy should have resolved

Exclusion Criteria:

Pregnancy or lactation at the time of study entry; (Note: pregnancy testing must be performed within 2 weeks prior to randomization according to institutional standards for women of childbearing potential)

Definitive clinical or radiologic evidence of metastatic disease

T4 tumors including inflammatory breast cancer

Documentation of axillary nodal positivity before neoadjuvant therapy by sentinel node biopsy alone

N2 or N3 disease detected clinically or by imaging

Patients with histologically positive axillary nodes post neoadjuvant therapy

Patients with microscopic positive margins after definitive surgery

Synchronous or previous contralateral invasive breast cancer or DCIS; (patients with synchronous and/or previous contralateral LCIS are eligible)

Any prior history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated with radiation therapy; (patients with synchronous or previous ipsilateral LCIS are eligible)

History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to randomization

Any radiation therapy for the currently diagnosed breast cancer prior to randomization

Any continued use of sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy; patients are eligible if these medications are discontinued prior to randomization

Prior breast or thoracic radiation therapy (RT) for any condition

Active collagen vascular disease, specifically dermatomyositis with a creatinine phosphokinase (CPK) level above normal or with an active skin rash, systemic lupus erythematosus, or scleroderma

Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up

Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

NRG Oncology

  • National Cancer Institute
  • Radiation Therapy Oncology Group
Eleftherios (Terry) Paul Mamounas, Principal Investigator

Trial Sites

U.S.A.

Alabama
Birmingham

University of Alabama at Birmingham Cancer Center

Jennifer F. De Los Santos
Ph: 888-823-5923
Email: ctsucontact@westat.com

Jennifer F. De Los Santos
Principal Investigator

Mobile

University of South Alabama Mitchell Cancer Institute

John R. Russell
Ph: 877-904-4367
Email: pfrancisco@usouthal.edu

John R. Russell
Principal Investigator

Alaska
Anchorage

Providence Alaska Medical Center

Alison Katherine Conlin
Ph: 503-215-6412

Alison Katherine Conlin
Principal Investigator

Arizona
Tucson

Arizona Oncology Associates-West Orange Grove

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Arkansas
Little Rock

University of Arkansas for Medical Sciences

Matthew E. Hardee
Ph: 501-686-8274

Matthew E. Hardee
Principal Investigator

California
Auburn

Sutter Cancer Centers Radiation Oncology Services-Auburn

Stacy D. D'Andre
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Stacy D. D'Andre
Principal Investigator

Cameron Park

Sutter Cancer Centers Radiation Oncology Services-Cameron Park

Stacy D. D'Andre
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Stacy D. D'Andre
Principal Investigator

Duarte

City of Hope Comprehensive Cancer Center

Lily Lau Lai
Ph: 800-826-4673
Email: becomingapatient@coh.org

Lily Lau Lai
Principal Investigator

Fresno

California Cancer Center - North Fresno

Uma G. Swamy
Ph: 559-447-4050

Uma G. Swamy
Principal Investigator

La Jolla

UC San Diego Moores Cancer Center

Anne Marie Duquette Wallace
Ph: 858-822-5354
Email: cancercto@ucsd.edu

Anne Marie Duquette Wallace
Principal Investigator

Los Angeles

Cedars-Sinai Medical Center

Christiane Michele J Burnison
Ph: 310-423-8965

Christiane Michele J Burnison
Principal Investigator

Los Angeles County-USC Medical Center

Eugene I. Chung
Ph: 323-865-0451

Eugene I. Chung
Principal Investigator

USC / Norris Comprehensive Cancer Center

Eugene I. Chung
Ph: 323-865-0451

Eugene I. Chung
Principal Investigator

Oakland

Alta Bates Summit Medical Center - Summit Campus

James Henry Feusner
Ph: 510-450-7600

James Henry Feusner
Principal Investigator

Kaiser Permanente Oakland-Broadway

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Orange

Saint Joseph Hospital - Orange

David Andrew Margileth
Ph: 714-734-6220

David Andrew Margileth
Principal Investigator

UC Irvine Health/Chao Family Comprehensive Cancer Center

Parima Daroui
Ph: 877-827-8839
Email: ucstudy@uci.edu

Parima Daroui
Principal Investigator

Palo Alto

Stanford Cancer Institute

Kathleen Claire Horst
Ph: 650-498-7061
Email: ccto-office@stanford.edu

Kathleen Claire Horst
Principal Investigator

Pasadena

Huntington Memorial Hospital

Ruth Chandler Williamson
Ph: 626-535-2420

Ruth Chandler Williamson
Principal Investigator

Pomona

Pomona Valley Hospital Medical Center

Yallapragada S. (Ram) Rao
Ph: 909-865-9555

Yallapragada S. (Ram) Rao
Principal Investigator

Rancho Cordova

Kaiser Permanente-Rancho Cordova Cancer Center

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Rohnert Park

Rohnert Park Cancer Center

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Roseville

Kaiser Permanente-Roseville

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Sutter Roseville Medical Center

Stacy D. D'Andre
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Stacy D. D'Andre
Principal Investigator

The Permanente Medical Group-Roseville Radiation Oncology

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Sacramento

Sutter General Hospital

Stacy D. D'Andre
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Stacy D. D'Andre
Principal Investigator

University of California Davis Comprehensive Cancer Center

Jyoti S. Mayadev
Ph: 916-734-3089

Jyoti S. Mayadev
Principal Investigator

Saint Helena

Saint Helena Hospital

Gregory B. Smith
Ph: 707-967-3698

Gregory B. Smith
Principal Investigator

San Diego

Naval Medical Center -San Diego

Craig D. Norris
Ph: 619-532-8712

Craig D. Norris
Principal Investigator

Santa Clara

Kaiser Permanente Medical Center - Santa Clara

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

South Pasadena

City of Hope South Pasadena

Lily Lau Lai
Ph: 800-826-4673
Email: becomingapatient@coh.org

Lily Lau Lai
Principal Investigator

South San Francisco

Kaiser Permanente-South San Francisco

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Truckee

Tahoe Forest Cancer Center

Jyoti S. Mayadev
Ph: 916-734-3089

Jyoti S. Mayadev
Principal Investigator

Vacaville

Sutter Cancer Centers Radiation Oncology Services-Vacaville

Stacy D. D'Andre
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Stacy D. D'Andre
Principal Investigator

Vallejo

Sutter Solano Medical Center/Cancer Center

Stacy D. D'Andre
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Stacy D. D'Andre
Principal Investigator

Colorado
Aurora

Rocky Mountain Cancer Centers-Aurora

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

University of Colorado Cancer Center - Anschutz Cancer Pavilion

Rachel Abrams Rabinovitch
Ph: 720-848-0650

Rachel Abrams Rabinovitch
Principal Investigator

Boulder

Rocky Mountain Cancer Centers-Boulder

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Colorado Springs

Memorial Hospital Colorado Springs

Rachel Abrams Rabinovitch
Ph: 720-848-0650

Rachel Abrams Rabinovitch
Principal Investigator

Penrose-Saint Francis Healthcare

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Denver

Porter Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Fort Collins

Poudre Valley Hospital

Rachel Abrams Rabinovitch
Ph: 720-848-0650

Rachel Abrams Rabinovitch
Principal Investigator

Littleton

Rocky Mountain Cancer Centers-Littleton

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Thornton

Rocky Mountain Cancer Centers-Thornton

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Wheat Ridge

SCL Health Lutheran Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Connecticut
Hartford

Hartford Hospital

Helaine F. Bertsch
Ph: 860-545-5363

Helaine F. Bertsch
Principal Investigator

New Britain

The Hospital of Central Connecticut

Neal B. Goldberg
Ph: 860-224-5660

Neal B. Goldberg
Principal Investigator

District of Columbia
Washington

MedStar Georgetown University Hospital

Edward C. McCarron
Ph: 443-777-7364

Edward C. McCarron
Principal Investigator

Sibley Memorial Hospital

Jean Lundberg Wright
Ph: 410-955-8804
Email: jhcccro@jhmi.edu

Jean Lundberg Wright
Principal Investigator

Washington Hospital Center

Edward C. McCarron
Ph: 443-777-7364

Edward C. McCarron
Principal Investigator

Florida
Atlantis

John Fitzgerald Kennedy Medical Center

Beth-Ann Lesnikoski
Ph: 888-823-5923
Email: ctsucontact@westat.com

Beth-Ann Lesnikoski
Principal Investigator

Deerfield Beach

University of Miami Sylvester Comprehensive Cancer Center at Deerfield Beach

Cristiane Takita
Ph: 866-574-5124
Email: Sylvester@emergingmed.com

Cristiane Takita
Principal Investigator

Gainesville

University of Florida

Judith L. Lightsey
Ph: 352-273-8675
Email: trials@cancer.ufl.edu

Judith L. Lightsey
Principal Investigator

Hollywood

Memorial Regional Hospital/Joe DiMaggio Children's Hospital

Srinath Sundararaman
Ph: 954-265-2234

Srinath Sundararaman
Principal Investigator

Miami

Baptist Hospital of Miami

Alan Albert Lewin
Ph: 800-599-2456
Email: cancerinfo@baptisthealth.net

Alan Albert Lewin
Principal Investigator

Jackson Memorial Hospital-Holtz Children's Hospital

Cristiane Takita
Ph: 866-574-5124
Email: Sylvester@emergingmed.com

Cristiane Takita
Principal Investigator

South Miami Hospital

Maria-Amelia M. Rodrigues
Ph: 888-823-5923
Email: ctsucontact@westat.com

Maria-Amelia M. Rodrigues
Principal Investigator

University of Miami Miller School of Medicine-Sylvester Cancer Center

Cristiane Takita
Ph: 866-574-5124
Email: Sylvester@emergingmed.com

Cristiane Takita
Principal Investigator

Orlando

Florida Hospital Orlando

Carlos Alberto Alemany
Ph: 407-303-5623

Carlos Alberto Alemany
Principal Investigator

UF Cancer Center at Orlando Health

Tomas Dvorak
Ph: 321-841-7246
Email: CancerClinicalTrials@orlandohealth.com

Tomas Dvorak
Principal Investigator

Georgia
Atlanta

Emory University/Winship Cancer Institute

Mylin Ann Torres
Ph: 404-778-1868

Mylin Ann Torres
Principal Investigator

Mylin Ann Torres
Ph: 404-778-1868

Mylin Ann Torres
Principal Investigator

Grady Health System

Mylin Ann Torres
Ph: 404-778-1868

Mylin Ann Torres
Principal Investigator

Piedmont Hospital

Adam Wayne Nowlan
Ph: 404-425-7943
Email: ORS@piedmont.org

Adam Wayne Nowlan
Principal Investigator

Saint Joseph's Hospital of Atlanta

Mylin Ann Torres
Ph: 404-778-1868

Mylin Ann Torres
Principal Investigator

Carrollton

Tanner Medical Center/Carrollton

James Richard Bland
Ph: 770-836-9824

James Richard Bland
Principal Investigator

Decatur

Dekalb Medical Center

Jayanthi Srinivasiah
Ph: 404-501-3279

Jayanthi Srinivasiah
Principal Investigator

Savannah

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

John A. Pablo
Ph: 800-622-6877

John A. Pablo
Principal Investigator

Memorial University Medical Center

Harvey Charles Lebos
Ph: 912-350-8568

Harvey Charles Lebos
Principal Investigator

Hawaii
Ewa Beach

The Cancer Center of Hawaii-Leeward

Kenneth N.M. Sumida
Ph: 808-586-2979
Email: dorothy@crch.hawaii.edu

Kenneth N.M. Sumida
Principal Investigator

Honolulu

Queen's Medical Center

Kenneth N.M. Sumida
Ph: 808-586-2979
Email: dorothy@crch.hawaii.edu

Kenneth N.M. Sumida
Principal Investigator

The Cancer Center of Hawaii-Liliha

Kenneth N.M. Sumida
Ph: 808-586-2979
Email: dorothy@crch.hawaii.edu

Kenneth N.M. Sumida
Principal Investigator

Idaho
Boise

Saint Alphonsus Cancer Care Center-Boise

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Illinois
Chicago

Advocate Illinois Masonic Medical Center

Paige L. Dorn
Ph: 773-296-5360

Paige L. Dorn
Principal Investigator

John H Stroger Jr Hospital of Cook County

Thomas E. Lad
Ph: 312-864-6000

Thomas E. Lad
Principal Investigator

Mount Sinai Hospital Medical Center

Pam G. Khosla
Ph: 773-257-5960
Email: suhi@sinai.org

Pam G. Khosla
Principal Investigator

University of Chicago Comprehensive Cancer Center

Steven J. Chmura
Ph: 773-834-7424

Steven J. Chmura
Principal Investigator

Decatur

Decatur Memorial Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Maywood

Loyola University Medical Center

Tarita O. Thomas
Ph: 708-226-4357

Tarita O. Thomas
Principal Investigator

Naperville

Edward Hospital/Cancer Center

Vasudha Lingareddy
Ph: 630-646-6075

Vasudha Lingareddy
Principal Investigator

New Lennox

UC Comprehensive Cancer Center at Silver Cross

Steven J. Chmura
Ph: 773-834-7424

Steven J. Chmura
Principal Investigator

Park Ridge

Advocate Lutheran General Hospital

Jacob David Bitran
Ph: 847-384-3621

Jacob David Bitran
Principal Investigator

Peoria

Illinois CancerCare-Peoria

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

OSF Saint Francis Medical Center

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Warrenville

Cadence Cancer Center in Warrenville

Christy M. Kesslering
Ph: 630-352-5300

Christy M. Kesslering
Principal Investigator

Indiana
Anderson

Saint Vincent Anderson Regional Hospital/Cancer Center

Alexander M. Yeh
Ph: 765-646-8358

Alexander M. Yeh
Principal Investigator

Goshen

IU Health Goshen Center for Cancer Care

Laura L. Morris
Ph: 574-535-2858

Laura L. Morris
Principal Investigator

Indianapolis

Community Hospital East

Shih Jack Wei
Ph: 317-621-7104

Shih Jack Wei
Principal Investigator

Community Regional Cancer Care-North

Shih Jack Wei
Ph: 317-621-7104

Shih Jack Wei
Principal Investigator

Indiana University/Melvin and Bren Simon Cancer Center

Mark Peter Langer
Ph: 317-274-2552

Mark Peter Langer
Principal Investigator

South Bend

Memorial Hospital of South Bend

Thomas Joseph Reid
Ph: 800-284-7370

Thomas Joseph Reid
Principal Investigator

Iowa
Clive

Mercy Cancer Center-West Lakes

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Des Moines

Iowa Methodist Medical Center

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Mercy Medical Center - Des Moines

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Iowa City

University of Iowa/Holden Comprehensive Cancer Center

Alexandra Thomas
Ph: 800-237-1225

Alexandra Thomas
Principal Investigator

Kansas
Kansas City

University of Kansas Cancer Center

Parvesh Kumar
Ph: 913-945-7552
Email: ctnursenav@kumc.edu

Parvesh Kumar
Principal Investigator

Overland Park

Kansas City Cancer Centers-Southwest

Parvesh Kumar
Ph: 913-945-7552
Email: ctnursenav@kumc.edu

Parvesh Kumar
Principal Investigator

Kentucky
Louisville

Baptist Health Louisville

James B. Eckman
Ph: 502-897-8592
Email: Cbcresearch@bhsi.com

James B. Eckman
Principal Investigator

The James Graham Brown Cancer Center at University of Louisville

Anthony Edward Dragun
Ph: 866-530-5516

Anthony Edward Dragun
Principal Investigator

Owensboro

Owensboro Health Mitchell Memorial Cancer Center

Samuel Ryan Faught
Ph: 270-688-3691
Email: shawns@omhs.org

Samuel Ryan Faught
Principal Investigator

Louisiana
New Orleans

Ochsner Medical Center Jefferson

Mini J. Elnaggar
Ph: 888-562-4763

Mini J. Elnaggar
Principal Investigator

Maine
Bangor

Eastern Maine Medical Center

Thomas H. Openshaw
Ph: 207-973-4274

Thomas H. Openshaw
Principal Investigator

Maryland
Annapolis

Anne Arundel Medical Center

Mary E. Young
Ph: 443-481-1320
Email: kbodenhorn@aahs.org

Mary E. Young
Principal Investigator

Baltimore

Johns Hopkins University/Sidney Kimmel Cancer Center

Jean Lundberg Wright
Ph: 410-955-8804
Email: jhcccro@jhmi.edu

Jean Lundberg Wright
Principal Investigator

MedStar Franklin Square Medical Center/Weinberg Cancer Institute

Edward C. McCarron
Ph: 443-777-7364

Edward C. McCarron
Principal Investigator

University of Maryland/Greenebaum Cancer Center

Steven J. Feigenberg
Ph: 800-888-8823

Steven J. Feigenberg
Principal Investigator

Bel Air

Upper Chesapeake Medical Center

Steven J. Feigenberg
Ph: 800-888-8823

Steven J. Feigenberg
Principal Investigator

Columbia

Central Maryland Radiation Oncology in Howard County

Steven J. Feigenberg
Ph: 800-888-8823

Steven J. Feigenberg
Principal Investigator

Glen Burnie

Tate Cancer Center

Steven J. Feigenberg
Ph: 800-888-8823

Steven J. Feigenberg
Principal Investigator

Massachusetts
Boston

Boston Medical Center

Ariel Elysse Hirsch
Ph: 617-638-8265

Ariel Elysse Hirsch
Principal Investigator

Dana-Farber Cancer Institute

Faina Nakhlis
Ph: 617-983-7000

Faina Nakhlis
Principal Investigator

Lowell

Lowell General Hospital

Matthew Strauss Katz
Ph: 978-788-7084
Email: ghincks@lowellgeneral.org

Matthew Strauss Katz
Principal Investigator

Michigan
Ann Arbor

University of Michigan Comprehensive Cancer Center

Lori J. Pierce
Ph: 800-865-1125

Lori J. Pierce
Principal Investigator

Clinton Township

Henry Ford Macomb Hospital

Thomas J. Doyle
Ph: 313-916-1784

Thomas J. Doyle
Principal Investigator

Detroit

Henry Ford Hospital

Thomas J. Doyle
Ph: 313-916-1784

Thomas J. Doyle
Principal Investigator

Saint John Hospital and Medical Center

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Flint

Genesys Hurley Cancer Institute

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Hurley Medical Center

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Grand Rapids

Spectrum Health at Butterworth Campus

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Lansing

Sparrow Hospital

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Muskegon

Mercy Health Mercy Campus

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Pontiac

Saint Joseph Mercy Oakland

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Royal Oak

William Beaumont Hospital-Royal Oak

Nayana S. Dekhne
Ph: 248-551-7695

Nayana S. Dekhne
Principal Investigator

Trenton

Downriver Center for Oncology

Thomas J. Doyle
Ph: 313-916-1784

Thomas J. Doyle
Principal Investigator

Troy

William Beaumont Hospital - Troy

Nayana S. Dekhne
Ph: 248-551-7695

Nayana S. Dekhne
Principal Investigator

Warren

Saint John Macomb-Oakland Hospital

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

West Bloomfield

Henry Ford Medical Center - West Bloomfield

Thomas J. Doyle
Ph: 313-916-1784

Thomas J. Doyle
Principal Investigator

Minnesota
Fridley

Unity Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Mankato

Mayo Clinic Health Systems-Mankato

Ron S. Smith
Ph: 507-385-2929

Ron S. Smith
Principal Investigator

Minneapolis

Abbott-Northwestern Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Rochester

Mayo Clinic

Robert W. Mutter
Ph: 507-538-7623

Robert W. Mutter
Principal Investigator

Saint Cloud

Coborn Cancer Center at Saint Cloud Hospital

Barbi L. Kaplan-Frenkel
Ph: 800-432-6049
Email: coborncancercenter@centracare.com

Barbi L. Kaplan-Frenkel
Principal Investigator

Saint Paul

United Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Waconia

Ridgeview Medical Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Missouri
Chesterfield

Saint Luke's Hospital

Donald F. Busiek
Ph: 314-205-6936

Donald F. Busiek
Principal Investigator

Kansas City

Kansas City Cancer Center - South

Parvesh Kumar
Ph: 913-945-7552
Email: ctnursenav@kumc.edu

Parvesh Kumar
Principal Investigator

Kansas City Cancer Centers - North

Parvesh Kumar
Ph: 913-945-7552
Email: ctnursenav@kumc.edu

Parvesh Kumar
Principal Investigator

North Kansas City Hospital

Parvesh Kumar
Ph: 913-945-7552
Email: ctnursenav@kumc.edu

Parvesh Kumar
Principal Investigator

Research Medical Center

Rakesh Gaur
Ph: 816-932-2677
Email: SLCIResearch1@saint-lukes.org

Rakesh Gaur
Principal Investigator

Saint Luke's Hospital of Kansas City

Rakesh Gaur
Ph: 816-932-2677
Email: SLCIResearch1@saint-lukes.org

Rakesh Gaur
Principal Investigator

Lee's Summit

Kansas City Cancer Center-Lee's Summit

Parvesh Kumar
Ph: 913-945-7552
Email: ctnursenav@kumc.edu

Parvesh Kumar
Principal Investigator

Saint Louis

Barnes-Jewish West County Hospital

Maria Anne Thomas
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Maria Anne Thomas
Principal Investigator

Washington University School of Medicine

Maria Anne Thomas
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Maria Anne Thomas
Principal Investigator

Saint Peters

Siteman Cancer Center - Saint Peters

Maria Anne Thomas
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Maria Anne Thomas
Principal Investigator

Montana
Great Falls

Benefis Healthcare- Sletten Cancer Institute

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Kalispell

Kalispell Regional Medical Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Nebraska
Grand Island

CHI Health Saint Francis

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Omaha

Alegent Health Lakeside Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Nevada
Las Vegas

Radiation Oncology Centers of Nevada Central

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Reno

Renown Regional Medical Center

Michael Chandler Hardacre
Ph: 775-982-4400

Michael Chandler Hardacre
Principal Investigator

New Hampshire
Concord

Concord Hospital

Su K. Metcalfe
Ph: 800-441-1138

Su K. Metcalfe
Principal Investigator

Lebanon

Dartmouth Hitchcock Medical Center

Alan Charles Hartford
Ph: 800-639-6918
Email: cancer.research.nurse@dartmouth.edu

Alan Charles Hartford
Principal Investigator

Manchester

Elliot Hospital

Brian Robert Knab
Ph: 603-663-1800

Brian Robert Knab
Principal Investigator

New Jersey
Basking Ridge

Memorial Sloan Kettering Cancer Center at Basking Ridge

Beryl McCormick
Ph: 212-639-7202

Beryl McCormick
Principal Investigator

Camden

Cooper Hospital University Medical Center

Tamara Anne LaCouture
Ph: 856-325-6757

Tamara Anne LaCouture
Principal Investigator

Livingston

Saint Barnabas Medical Center

Alison Grann
Ph: 973-322-2470

Alison Grann
Principal Investigator

Mount Holly

Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County

Lemuel S. Ariaratnam
Ph: 888-847-8823

Lemuel S. Ariaratnam
Principal Investigator

New Brunswick

UMDNJ - Robert Wood Johnson University Hospital

Atif Jalees Khan
Ph: 732-235-8675

Atif Jalees Khan
Principal Investigator

Paramus

The Valley Hospital-Luckow Pavilion

Laura A. Klein
Ph: 201-634-5792

Laura A. Klein
Principal Investigator

Ridgewood

Valley Hospital

Laura A. Klein
Ph: 201-634-5792

Laura A. Klein
Principal Investigator

Sparta

Sparta Cancer Treatment Center

Pramila Rani Anne
Ph: 215-955-6084

Pramila Rani Anne
Principal Investigator

Voorhees

MD Anderson Cancer Center at Cooper-Voorhees

Tamara Anne LaCouture
Ph: 856-325-6757

Tamara Anne LaCouture
Principal Investigator

Virtua West Jersey Hospital Voorhees

Lemuel S. Ariaratnam
Ph: 888-847-8823

Lemuel S. Ariaratnam
Principal Investigator

Westwood

Oncology Hematology and Internal Medicine

Laura A. Klein
Ph: 201-634-5792

Laura A. Klein
Principal Investigator

New Mexico
Albuquerque

University of New Mexico

Benny J. Liem
Ph: 505-272-6972

Benny J. Liem
Principal Investigator

New York
Commack

Memorial Sloan Kettering Cancer Center Commack

Beryl McCormick
Ph: 212-639-7202

Beryl McCormick
Principal Investigator

Cooperstown

Mary Imogene Bassett Hospital

Joy E. Anderson
Ph: 607-547-3073
Email: diana.crean@bassett.org

Joy E. Anderson
Principal Investigator

New York

Columbia University Medical Center

Eileen Patricia Connolly
Ph: 212-305-8615

Eileen Patricia Connolly
Principal Investigator

Memorial Sloan-Kettering Cancer Center

Beryl McCormick
Ph: 212-639-7202

Beryl McCormick
Principal Investigator

Poughkeepsie

Vassar Brothers Medical Center

Gregory John Zanieski
Ph: 845-483-6483

Gregory John Zanieski
Principal Investigator

Rockville Centre

Memorial Sloan-Kettering Cancer Center Rockville Centre

Beryl McCormick
Ph: 212-639-7202

Beryl McCormick
Principal Investigator

Sleepy Hollow

Memorial Sloan-Kettering Cancer Center Sleepy Hollow

Beryl McCormick
Ph: 212-639-7202

Beryl McCormick
Principal Investigator

West Harrison

Memorial Sloan-Kettering Cancer Center West Harrison

Beryl McCormick
Ph: 212-639-7202

Beryl McCormick
Principal Investigator

North Carolina
Charlotte

Carolinas Medical Center/Levine Cancer Institute

Hadley J. Sharp
Ph: 704-355-2884

Hadley J. Sharp
Principal Investigator

CMC-LCI Radiation Therapy-Pineville

Hadley J. Sharp
Ph: 704-355-2884

Hadley J. Sharp
Principal Investigator

Novant Health Presbyterian Medical Center

Justin Peter Favaro
Ph: 704-384-5369

Justin Peter Favaro
Principal Investigator

University Radiation Therapy Center

Hadley J. Sharp
Ph: 704-355-2884

Hadley J. Sharp
Principal Investigator

Concord

Carolinas HealthCare System NorthEast

Hadley J. Sharp
Ph: 704-355-2884

Hadley J. Sharp
Principal Investigator

Durham

Duke University Medical Center

Rachel C. Blitzblau
Ph: 888-275-3853

Rachel C. Blitzblau
Principal Investigator

Gastonia

Gaston Memorial Hospital

Charles J. Meakin
Ph: 704-834-2932

Charles J. Meakin
Principal Investigator

Greensboro

Cone Health Cancer Center

James Mitchell Granfortuna
Ph: 336-832-0821

James Mitchell Granfortuna
Principal Investigator

Greenville

East Carolina University

Eleanor E.R. Harris
Ph: 252-744-2391

Eleanor E.R. Harris
Principal Investigator

Matthews

Matthews Radiation Oncology Center

Justin Peter Favaro
Ph: 704-384-5369

Justin Peter Favaro
Principal Investigator

Monroe

Carolinas HealthCare System Union

Hadley J. Sharp
Ph: 704-355-2884

Hadley J. Sharp
Principal Investigator

Supply

South Atlantic Radiation Oncology

Michael A. Papagikos
Ph: 910-251-1839

Michael A. Papagikos
Principal Investigator

Wilmington

Coastal Carolina Radiation Oncology

Michael A. Papagikos
Ph: 910-251-1839

Michael A. Papagikos
Principal Investigator

North Dakota
Bismarck

Sanford Bismarck Medical Center

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Ohio
Akron

Akron General Medical Center

Andrew H. Fenton
Ph: 330-344-6348

Andrew H. Fenton
Principal Investigator

Summa Akron City Hospital/Cooper Cancer Center

Jennifer Eileen Payne
Ph: 330-375-6101

Jennifer Eileen Payne
Principal Investigator

Barberton

Summa Barberton Hospital

Jennifer Eileen Payne
Ph: 330-375-6101

Jennifer Eileen Payne
Principal Investigator

Beachwood

UHHS-Chagrin Highlands Medical Center

Robert R. Shenk
Ph: 800-641-2422

Robert R. Shenk
Principal Investigator

Canton

Aultman Health Foundation

Shruti Trehan
Ph: 330-363-6891

Shruti Trehan
Principal Investigator

Chardon

Geaugra Hospital

Robert R. Shenk
Ph: 800-641-2422

Robert R. Shenk
Principal Investigator

Cincinnati

Bethesda North Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Good Samaritan Hospital - Cincinnati

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

University of Cincinnati

Kevin Patrick Redmond
Ph: 513-558-4553
Email: uchealthnews@uc.edu

Kevin Patrick Redmond
Principal Investigator

Cleveland

Case Western Reserve University

Robert R. Shenk
Ph: 800-641-2422

Robert R. Shenk
Principal Investigator

Cleveland Clinic Cancer Center/Fairview Hospital

Rahul Dilip Tendulkar
Ph: 866-223-8100

Rahul Dilip Tendulkar
Principal Investigator

Cleveland Clinic Foundation

Rahul Dilip Tendulkar
Ph: 866-223-8100

Rahul Dilip Tendulkar
Principal Investigator

Columbus

Ohio State University Comprehensive Cancer Center

Julia R. White
Ph: 800-293-5066
Email: Jamesline@osumc.edu

Julia R. White
Principal Investigator

The Mark H Zangmeister Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Delaware

Delaware Radiation Oncology

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Independence

Cleveland Clinic Cancer Center Independence

Rahul Dilip Tendulkar
Ph: 866-223-8100

Rahul Dilip Tendulkar
Principal Investigator

Mayfield Heights

Hillcrest Hospital Cancer Center

Rahul Dilip Tendulkar
Ph: 866-223-8100

Rahul Dilip Tendulkar
Principal Investigator

Medina

Summa Health Center at Lake Medina

Jennifer Eileen Payne
Ph: 330-375-6101

Jennifer Eileen Payne
Principal Investigator

Mentor

Lake University Ireland Cancer Center

Robert R. Shenk
Ph: 800-641-2422

Robert R. Shenk
Principal Investigator

Middleburg Heights

Southwest General Health Center Ireland Cancer Center

Robert R. Shenk
Ph: 800-641-2422

Robert R. Shenk
Principal Investigator

Sandusky

North Coast Cancer Care

Rahul Dilip Tendulkar
Ph: 866-223-8100

Rahul Dilip Tendulkar
Principal Investigator

Strongsville

Cleveland Clinic Cancer Center Strongsville

Rahul Dilip Tendulkar
Ph: 866-223-8100

Rahul Dilip Tendulkar
Principal Investigator

West Chester

University Pointe

Kevin Patrick Redmond
Ph: 513-558-4553
Email: uchealthnews@uc.edu

Kevin Patrick Redmond
Principal Investigator

Westlake

UHHS-Westlake Medical Center

Robert R. Shenk
Ph: 800-641-2422

Robert R. Shenk
Principal Investigator

Wooster

Cleveland Clinic Wooster Specialty Center

Rahul Dilip Tendulkar
Ph: 866-223-8100

Rahul Dilip Tendulkar
Principal Investigator

Oklahoma
Lawton

Cancer Centers of Southwest Oklahoma Research

Nadim Fouad Nimeh
Ph: 877-231-4440

Nadim Fouad Nimeh
Principal Investigator

Oklahoma City

Mercy Hospital Oklahoma City

Astrid Elizabeth Morrison
Ph: 405-751-4343

Astrid Elizabeth Morrison
Principal Investigator

University of Oklahoma Health Sciences Center

Terence S. Herman
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

Terence S. Herman
Principal Investigator

Oregon
Eugene

Willamette Valley Cancer Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Gresham

Legacy Mount Hood Medical Center

Andrew Y. Kee
Ph: 800-220-4937
Email: cancer@lhs.org

Andrew Y. Kee
Principal Investigator

Pennsylvania
Allentown

Lehigh Valley Hospital-Cedar Crest

Alyson F. McIntosh
Ph: 610-402-2273

Alyson F. McIntosh
Principal Investigator

Beaver

UPMC-Heritage Valley Health System Beaver

Sushil Beriwal
Ph: 412-647-2811

Sushil Beriwal
Principal Investigator

Bethlehem

Saint Luke's University Hospital-Bethlehem Campus

Nimisha Deb
Ph: 610-954-3582
Email: infolink@slhn.org

Nimisha Deb
Principal Investigator

Dunmore

Northeast Radiation Oncology Center

Pramila Rani Anne
Ph: 215-955-6084

Pramila Rani Anne
Principal Investigator

Erie

The Regional Cancer Center

Andrew Thomas Figura
Ph: 814-838-0448
Email: mhaynes@trcc.org

Andrew Thomas Figura
Principal Investigator

Furlong

Fox Chase Cancer Center Buckingham

Penny Rawdin Anderson
Ph: 215-728-4790

Penny Rawdin Anderson
Principal Investigator

Gettysburg

Adams Cancer Center

L. Eamonn Boyle
Ph: 877-441-7957

L. Eamonn Boyle
Principal Investigator

Harrisburg

PinnacleHealth Cancer Center-Community Campus

Brij M. Sood
Ph: 717-724-6765
Email: klitchfield@PINNACLEHEALTH.org

Brij M. Sood
Principal Investigator

Hershey

Penn State Milton S Hershey Medical Center

Jennifer C. Rosenberg
Ph: 717-531-3779
Email: CTO@hmc.psu.edu

Jennifer C. Rosenberg
Principal Investigator

Lancaster

Lancaster General Hospital

Jeffery S. Eshleman
Ph: 717-544-5511

Jeffery S. Eshleman
Principal Investigator

Monroeville

Intercommunity Cancer Center

Thomas Benjamin Julian
Ph: 877-284-2000

Thomas Benjamin Julian
Principal Investigator

Natrona Heights

Allegheny Valley Hospital

Thomas Benjamin Julian
Ph: 877-284-2000

Thomas Benjamin Julian
Principal Investigator

Philadelphia

Fox Chase Cancer Center

Penny Rawdin Anderson
Ph: 215-728-4790

Penny Rawdin Anderson
Principal Investigator

Thomas Jefferson University Hospital

Pramila Rani Anne
Ph: 215-955-6084

Pramila Rani Anne
Principal Investigator

Pittsburgh

Allegheny General Hospital

Thomas Benjamin Julian
Ph: 877-284-2000

Thomas Benjamin Julian
Principal Investigator

UPMC-Shadyside Hospital

Sushil Beriwal
Ph: 412-647-2811

Sushil Beriwal
Principal Investigator

West Reading

Reading Hospital

Terrence Paul Cescon
Ph: 610-988-9323

Terrence Paul Cescon
Principal Investigator

Wexford

Wexford Health and Wellness Pavilion

Thomas Benjamin Julian
Ph: 877-284-2000

Thomas Benjamin Julian
Principal Investigator

York

WellSpan Health-York Hospital

L. Eamonn Boyle
Ph: 877-441-7957

L. Eamonn Boyle
Principal Investigator

Rhode Island
Providence

Rhode Island Hospital

Kara Lynne Leonard
Ph: 401-444-1488

Kara Lynne Leonard
Principal Investigator

South Carolina
Charleston

Medical University of South Carolina

Jennifer L. Harper
Ph: 843-792-9321

Jennifer L. Harper
Principal Investigator

Roper Hospital

James Michael Orcutt
Ph: 843-720-8386
Email: elizabeth.strojny@roperstfrancis.com

James Michael Orcutt
Principal Investigator

Greenville

Greenville Health System Cancer Institute-Andrews

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Greenville Health System Cancer Institute-Eastside

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Greenville Health System Cancer Institute-Faris

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Greer

Gibbs Cancer Center-Pelham

Steven William Corso
Ph: 800-486-5941

Steven William Corso
Principal Investigator

Greenville Health System Cancer Institute-Greer

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Seneca

Greenville Health System Cancer Institute-Seneca

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Spartanburg

Greenville Health System Cancer Institute-Spartanburg

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Spartanburg Medical Center

Steven William Corso
Ph: 800-486-5941

Steven William Corso
Principal Investigator

South Dakota
Sioux Falls

Avera Cancer Institute

Amy K. Krie
Ph: 800-657-4377
Email: Jan.Healy@avera.org

Amy K. Krie
Principal Investigator

Sanford USD Medical Center - Sioux Falls

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Tennessee
Knoxville

Thompson Cancer Survival Center

Daniel D. Scaperoth
Ph: 865-541-1812

Daniel D. Scaperoth
Principal Investigator

Texas
Amarillo

The Don and Sybil Harrington Cancer Center

Daniel Arsenault
Ph: 806-359-4673
Email: ryokubaitis@harringtoncc.org

Daniel Arsenault
Principal Investigator

Austin

Texas Oncology - Central Austin Cancer Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Texas Oncology - South Austin Cancer Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Texas Oncology-Austin Midtown

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Bedford

Texas Oncology Bedford

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Flower Mound

Texas Oncology-Flower Mound

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Fort Worth

The Klabzuba Cancer Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Houston

M D Anderson Cancer Center

Simona F. Shaitelman
Ph: 713-792-3245

Simona F. Shaitelman
Principal Investigator

Memorial Hermann Memorial City Medical Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Laredo

Doctor's Hospital of Laredo

Gary Walter Unzeitig
Ph: 888-823-5923
Email: ctsucontact@westat.com

Gary Walter Unzeitig
Principal Investigator

Lubbock

Covenant Medical Center-Lakeside

Ibrahim Adly Shalaby
Ph: 806-725-8000
Email: jaccresearch@covhs.org

Ibrahim Adly Shalaby
Principal Investigator

Plano

Texas Oncology-Plano West

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Round Rock

Texas Oncology - Round Rock Cancer Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

San Antonio

University of Texas Health Science Center at San Antonio

Richard L. Crownover
Ph: 210-450-3800
Email: CTO@uthscsa.edu

Richard L. Crownover
Principal Investigator

Sugar Land

Texas Oncology Cancer Center Sugar Land

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Utah
Murray

Intermountain Medical Center

Vilija N. Avizonis
Ph: 801-507-3950

Vilija N. Avizonis
Principal Investigator

Salt Lake City

Huntsman Cancer Institute/University of Utah

Matthew M. Poppe
Ph: 801-581-4477
Email: clinical.trials@hci.utah.edu

Matthew M. Poppe
Principal Investigator

Vermont
Saint Johnsbury

Norris Cotton Cancer Center-North

Alan Charles Hartford
Ph: 800-639-6918
Email: cancer.research.nurse@dartmouth.edu

Alan Charles Hartford
Principal Investigator

Virginia
Alexandria

Inova Alexandria Hospital

Jane Grayson
Ph: 703-776-2580
Email: research@inova.org

Jane Grayson
Principal Investigator

Charlottesville

University of Virginia Cancer Center

Shayna Lefrak Showalter
Ph: 434-243-6143

Shayna Lefrak Showalter
Principal Investigator

Falls Church

Inova Fairfax Hospital

Ashish K. Chawla
Ph: 703-208-6650

Ashish K. Chawla
Principal Investigator

Hampton

Sentara Cancer Institute at Sentara CarePlex Hospital

Mark E. Shaves
Ph: 757-388-2406

Mark E. Shaves
Principal Investigator

Norfolk

Sentara Hospitals

Mark E. Shaves
Ph: 757-388-2406

Mark E. Shaves
Principal Investigator

Richmond

Virginia Commonwealth University/Massey Cancer Center

Harry Douglas Bear
Ph: 804-628-1939

Harry Douglas Bear
Principal Investigator

Roanoke

Oncology and Hematology Associates of Southwest Virginia

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Virginia Beach

Sentara Virginia Beach General Hospital

Mark E. Shaves
Ph: 757-388-2406

Mark E. Shaves
Principal Investigator

Washington
Bellevue

Overlake Hospital Medical Center

John A. Keech
Ph: 907-458-5380

John A. Keech
Principal Investigator

Bremerton

Harrison Medical Center

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Gig Harbor

Tacoma/Valley Radiation Oncology Centers-Gig Harbor

John A. Keech
Ph: 907-458-5380

John A. Keech
Principal Investigator

Kennewick

Tri-Cities Cancer Center

Janice Nam Kim
Ph: 800-804-8824

Janice Nam Kim
Principal Investigator

Mount Vernon

Skagit Valley Hospital Regional Cancer Care Center

Janice Nam Kim
Ph: 800-804-8824

Janice Nam Kim
Principal Investigator

Puyallup

MultiCare Good Samaritan Hospital

John A. Keech
Ph: 907-458-5380

John A. Keech
Principal Investigator

Tacoma/Valley Radiation Oncology Centers-Puyallup

John A. Keech
Ph: 907-458-5380

John A. Keech
Principal Investigator

Seattle

Seattle Cancer Care Alliance

Janice Nam Kim
Ph: 800-804-8824

Janice Nam Kim
Principal Investigator

Virginia Mason Medical Center

John A. Keech
Ph: 907-458-5380

John A. Keech
Principal Investigator

Spokane

Cancer Care Northwest - Spokane South

Janice Nam Kim
Ph: 800-804-8824

Janice Nam Kim
Principal Investigator

Spokane Valley Cancer Center-Mayfair

Janice Nam Kim
Ph: 800-804-8824

Janice Nam Kim
Principal Investigator

Tacoma

Multicare Health System

John A. Keech
Ph: 907-458-5380

John A. Keech
Principal Investigator

Northwest Medical Specialties PLLC

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Tacoma/Valley Radiation Oncology Centers-Saint Joe's

John A. Keech
Ph: 907-458-5380

John A. Keech
Principal Investigator

Vancouver

Compass Oncology Vancouver

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

West Virginia
Morgantown

West Virginia University Healthcare

Jessica Freeman Partin
Ph: 304-293-2745
Email: sfilburn@hsc.wvu.edu

Jessica Freeman Partin
Principal Investigator

Wisconsin
Appleton

Appleton Medical Center

Editha (Edie) A. Krueger
Ph: 920-380-1500

Editha (Edie) A. Krueger
Principal Investigator

Fox Valley Surgical Associates Limited

Honnie R. Bermas
Ph: 800-574-3872

Honnie R. Bermas
Principal Investigator

Eau Claire

Sacred Heart Hospital

Jessica A. Wernberg
Ph: 715-389-4457

Jessica A. Wernberg
Principal Investigator

Grafton

Aurora Cancer Care-Grafton

Ellen L. Ziaja
Ph: 800-252-2990

Ellen L. Ziaja
Principal Investigator

Green Bay

Aurora BayCare Medical Center

Ellen L. Ziaja
Ph: 800-252-2990

Ellen L. Ziaja
Principal Investigator

Saint Mary's Hospital

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Saint Vincent Hospital

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

La Crosse

Gundersen Lutheran Medical Center

Kurt Oettel
Ph: 608-775-2385
Email: cancerctr@gundluth.org

Kurt Oettel
Principal Investigator

Madison

University of Wisconsin Hospital and Clinics

Bethany Marie Anderson
Ph: 877-405-6866

Bethany Marie Anderson
Principal Investigator

Marshfield

Saint Joseph's Hospital

Jessica A. Wernberg
Ph: 715-389-4457

Jessica A. Wernberg
Principal Investigator

Menomonee Falls

Community Memorial Hospital

Adam D. Currey
Ph: 414-805-4380

Adam D. Currey
Principal Investigator

Milwaukee

Aurora Saint Luke's Medical Center

Ellen L. Ziaja
Ph: 800-252-2990

Ellen L. Ziaja
Principal Investigator

Froedtert and the Medical College of Wisconsin

Adam D. Currey
Ph: 414-805-4380

Adam D. Currey
Principal Investigator

Minocqua

Marshfield Clinic-Minocqua Center

Jessica A. Wernberg
Ph: 715-389-4457

Jessica A. Wernberg
Principal Investigator

Neenah

Surgical Associates of Neenah SC

Editha (Edie) A. Krueger
Ph: 920-380-1500

Editha (Edie) A. Krueger
Principal Investigator

Oconomowoc

Oconomowoc Memorial Hospital-ProHealth Care Inc

Wingate F. Clapper
Ph: 262-928-7632
Email: Chanda.miller@phci.org

Wingate F. Clapper
Principal Investigator

Oshkosh

Vince Lombardi Cancer Clinic - Oshkosh

Ellen L. Ziaja
Ph: 800-252-2990

Ellen L. Ziaja
Principal Investigator

Racine

Wheaton Franciscan Cancer Care - All Saints

James H. Taylor
Ph: 414-874-4541
Email: Kelli.holton@wfhc.org

James H. Taylor
Principal Investigator

Rice Lake

Marshfield Clinic-Rice Lake Center

Jessica A. Wernberg
Ph: 715-389-4457

Jessica A. Wernberg
Principal Investigator

Stevens Point

Saint Michael's Hospital

Jessica A. Wernberg
Ph: 715-389-4457

Jessica A. Wernberg
Principal Investigator

Summit

Aurora Medical Center in Summit

Ellen L. Ziaja
Ph: 800-252-2990

Ellen L. Ziaja
Principal Investigator

Two Rivers

Vince Lombardi Cancer Clinic

Ellen L. Ziaja
Ph: 800-252-2990

Ellen L. Ziaja
Principal Investigator

Waukesha

Waukesha Memorial Hospital

Wingate F. Clapper
Ph: 262-928-7632
Email: Chanda.miller@phci.org

Wingate F. Clapper
Principal Investigator

Wauwatosa

Aurora Cancer Care-Milwaukee West

Ellen L. Ziaja
Ph: 800-252-2990

Ellen L. Ziaja
Principal Investigator

West Allis

Aurora West Allis Medical Center

Ellen L. Ziaja
Ph: 800-252-2990

Ellen L. Ziaja
Principal Investigator

West Bend

The Alyce and Elmore Kraemer Cancer Care Center

Adam D. Currey
Ph: 414-805-4380

Adam D. Currey
Principal Investigator

Canada

Alberta
Calgary

Tom Baker Cancer Centre

Keith Tankel
Ph: 780-432-8500

Keith Tankel
Principal Investigator

Edmonton

Cross Cancer Institute

Keith Tankel
Ph: 780-432-8500

Keith Tankel
Principal Investigator

Quebec
Montreal

Hopital Maisonneuve-Rosemont

Michael Yassa
Ph: 514-252-3400ext3329

Michael Yassa
Principal Investigator

Jewish General Hospital

Thierry M. Muanza
Ph: 514-934-4400

Thierry M. Muanza
Principal Investigator

Quebec City

CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)

Valerie Theberge
Ph: 418-525-4444

Valerie Theberge
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01872975

Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.